KR20230007538A - 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법 - Google Patents

고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법 Download PDF

Info

Publication number
KR20230007538A
KR20230007538A KR1020227045465A KR20227045465A KR20230007538A KR 20230007538 A KR20230007538 A KR 20230007538A KR 1020227045465 A KR1020227045465 A KR 1020227045465A KR 20227045465 A KR20227045465 A KR 20227045465A KR 20230007538 A KR20230007538 A KR 20230007538A
Authority
KR
South Korea
Prior art keywords
patients
week
ser
alirocumab
ldl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227045465A
Other languages
English (en)
Korean (ko)
Inventor
코린 하노텡
로렝스 베작
우메쉬 차우다리
로버트 포디
다니엘 에이. 슈웨머 가이프
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Priority to KR1020247028498A priority Critical patent/KR20240132123A/ko
Publication of KR20230007538A publication Critical patent/KR20230007538A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227045465A 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법 Ceased KR20230007538A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020247028498A KR20240132123A (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US201462025371P 2014-07-16 2014-07-16
US62/025,371 2014-07-16
US201462043167P 2014-08-28 2014-08-28
US62/043,167 2014-08-28
US201462080725P 2014-11-17 2014-11-17
US62/080,725 2014-11-17
US201562132709P 2015-03-13 2015-03-13
US62/132,709 2015-03-13
EP15305830 2015-05-29
EP15305830.0 2015-05-29
PCT/US2015/040765 WO2016011260A1 (en) 2014-07-16 2015-07-16 Methods for treating high cardiovascular risk patients with hypercholesterolemia
KR1020177004219A KR102482375B1 (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177004219A Division KR102482375B1 (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028498A Division KR20240132123A (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법

Publications (1)

Publication Number Publication Date
KR20230007538A true KR20230007538A (ko) 2023-01-12

Family

ID=53365943

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227045465A Ceased KR20230007538A (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
KR1020247028498A Ceased KR20240132123A (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
KR1020177004219A Active KR102482375B1 (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020247028498A Ceased KR20240132123A (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
KR1020177004219A Active KR102482375B1 (ko) 2014-07-16 2015-07-16 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법

Country Status (12)

Country Link
US (2) US20160137746A1 (https=)
EP (2) EP3169362B1 (https=)
JP (1) JP6912374B2 (https=)
KR (3) KR20230007538A (https=)
CN (2) CN107106678A (https=)
AU (1) AU2015289617B2 (https=)
CA (1) CA2955304C (https=)
MX (2) MX378872B (https=)
PL (1) PL3169362T3 (https=)
RU (1) RU2723018C2 (https=)
WO (1) WO2016011260A1 (https=)
ZA (1) ZA201700196B (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
SG192117A1 (en) 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
HUE069234T2 (hu) 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
US10494442B2 (en) 2013-06-07 2019-12-03 Sanofi Biotechnology Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
CN118105480A (zh) 2013-11-12 2024-05-31 赛诺菲生物技术公司 用于与pcsk9抑制剂一起使用的给药方案
KR20230074283A (ko) 2014-07-16 2023-05-26 사노피 바이오테크놀로지 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
WO2016046684A1 (en) * 2014-09-23 2016-03-31 Pfizer Inc. Treatment with anti-pcsk9 antibodies
JP2018523684A (ja) 2015-08-18 2018-08-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
MA43734A (fr) 2016-03-03 2018-11-28 Regeneron Pharma Procédés de traitement de patients atteints d'hyperlipidémie par administration d'un inhibiteur de pcsk9 en combinaison avec un inhibiteur d'angptl3
TW201904608A (zh) * 2017-06-09 2019-02-01 法商賽諾菲生物技術公司 藉由投予ｐｃｓｋ９抑制劑治療糖尿病患者高血脂症之方法
TW201945401A (zh) * 2018-03-06 2019-12-01 法商賽諾菲生物技術公司 降低心血管風險的方法
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso
US12559551B2 (en) 2019-05-24 2026-02-24 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-ANGPTL3 antibodies
IL292973B2 (en) * 2019-11-18 2026-03-01 Ad Pharmaceuticals Co Ltd Anti-PCSK9 antibody and its use
CA3188213A1 (en) * 2020-08-07 2022-02-10 Robert C. Pordy Methods for treating refractory hypercholesterolemia involving an angptl3 inhibitor
CN116983434B (zh) * 2023-09-28 2024-03-15 康霖生物科技（杭州）有限公司 用于基因治疗的核酸构建体及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) * 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
SG192117A1 (en) * 2011-01-28 2013-08-30 Sanofi Sa Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
JOP20200043A1 (ar) * 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20130006482A1 (en) * 2011-06-30 2013-01-03 Ramadev Burigsay Hukkeri Guidance system for a mobile machine
HUE069234T2 (hu) * 2011-09-16 2025-02-28 Regeneron Pharma Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
EP2706070A1 (en) * 2012-09-06 2014-03-12 Sanofi Combination treatments involving antibodies to human PCSK9
EA039310B1 (ru) * 2015-02-26 2022-01-12 Санофи Байотекнолоджи Способы снижения сердечно-сосудистого риска

Also Published As

Publication number Publication date
AU2015289617B2 (en) 2021-04-15
CA2955304C (en) 2023-12-12
RU2017104799A (ru) 2018-08-16
KR20240132123A (ko) 2024-09-02
RU2017104799A3 (https=) 2019-02-19
ZA201700196B (en) 2024-09-25
EP3169362A1 (en) 2017-05-24
EP3169362B1 (en) 2020-06-10
PL3169362T3 (pl) 2020-12-28
KR102482375B1 (ko) 2022-12-29
MX378872B (es) 2025-03-11
CN107106678A (zh) 2017-08-29
WO2016011260A1 (en) 2016-01-21
RU2723018C2 (ru) 2020-06-08
CA2955304A1 (en) 2016-01-21
JP2017522316A (ja) 2017-08-10
CN114306592A (zh) 2022-04-12
MX2017000628A (es) 2017-04-27
US20160137746A1 (en) 2016-05-19
AU2015289617A1 (en) 2017-02-02
US20200255544A1 (en) 2020-08-13
KR20170028441A (ko) 2017-03-13
EP3753575A1 (en) 2020-12-23
JP6912374B2 (ja) 2021-08-04
MX2021000289A (es) 2021-03-31

Similar Documents

Publication Publication Date Title
KR102482375B1 (ko) 고콜레스테롤혈증이 있는 심혈관 위험이 높은 환자를 치료하는 방법
JP7467538B2 (ja) ヘテロ接合性家族性高コレステロール血症（ｈｅＦＨ）を有する患者を処置するための方法
US20220144969A1 (en) Methods for reducing cardiovascular risk
AU2014274077B2 (en) Methods for treating autosomal dominant hypercholesterolemia associated with PCSK9 gain-of-function mutations
US20150283236A1 (en) Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled
HK1236135A1 (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia
HK1236135B (en) Methods for treating high cardiovascular risk patients with hypercholesterolemia

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221223

Application number text: 1020177004219

Filing date: 20170215

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230412

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20240223

Patent event code: PE09021S02D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20240823

Application number text: 1020177004219

Filing date: 20170215

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240827

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D